What is EXEL's Value Score?

Exelixis, Inc. - Common Stock (EXEL) has a StockPik Value Score of 79 out of 100 — a high score, indicating strong value characteristics across multiple metrics. The Value Score is a composite ranking built from P/E ratio, P/B ratio, Graham Number, ROE, gross margin, debt-to-equity, current ratio, and Piotroski F-Score, calculated from SEC EDGAR annual filing data.

What is EXEL's Piotroski F-Score?

Exelixis, Inc. - Common Stock (EXEL) has a Piotroski F-Score of 6 out of 9 — a moderate score. The F-Score assesses nine binary financial criteria across profitability, leverage, and operating efficiency. A score of 7–9 indicates a financially improving company; a score of 0–3 is a warning sign.

Is EXEL trading below its Graham Number?

EXEL is currently trading above its Graham Number. The stock price of $48.7 exceeds the Graham Number of $22.72, meaning it does not meet Graham's criterion for a margin of safety at the current price. The Graham Number is calculated as √(22.5 × EPS × Book Value Per Share) and represents Benjamin Graham's ceiling price for a defensive investor.

What is EXEL's Graham Number?

EXEL's Graham Number is $22.72, calculated using the Benjamin Graham formula √(22.5 × EPS × Book Value per Share). The Graham Number is an estimate of intrinsic value — the maximum price a defensive investor should pay. At the current price of $48.70, EXEL is trading 114% above its Graham Number.

What is EXEL's Piotroski F-Score?

EXEL's Piotroski F-Score is 6 out of 9, indicating moderate financial health. The Piotroski F-Score evaluates nine criteria across profitability, leverage, and operating efficiency. Scores of 7 or above are considered strong; 3 or below indicate financial weakness.

Is EXEL (Exelixis, Inc. - Common Stock) undervalued?

EXEL scores 79/100 on StockPik's Value Score, placing it in undervalued territory. The stock trades 114% above its Graham Number of $22.72.

What is EXEL's P/E ratio?

EXEL's trailing P/E ratio is 16.4x — a reasonable earnings multiple. The Healthcare sector average P/E is 25.2x. Compare against other Healthcare stocks in the StockPik screener.

What sector is Exelixis, Inc. - Common Stock (EXEL) in?

Exelixis, Inc. - Common Stock (EXEL) is in the Healthcare sector, specifically in the Biological Products, (No Diagnostic Substances) industry. Compare it against other Healthcare stocks by Value Score, P/E ratio, and Piotroski F-Score on StockPik.

Back to Screener

Exelixis, Inc. - Common Stock (EXEL)

NASDAQ Large Cap

Healthcare › Biological Products, (No Diagnostic Substances)

$48.70

Market Cap: $12.2B

Data as of Apr 3, 2026 (TTM)

Price History

Feb 9, 2026 — May 7, 2026

Investment Snapshot

Trading 114% above Graham Number — above intrinsic value estimate
Piotroski F-Score 6/9 — moderate financial health
Strong ROE of 38.7% with 32.1% net margin
Revenue growing at 7% annually

Exelixis, Inc. - Common Stock (EXEL) is a Healthcare company operating in Biological Products, (No Diagnostic Substances), listed on the NASDAQ , with a market capitalisation of $12.2 billion . Key value metrics: P/E ratio 16.4, P/B ratio 6.32, Piotroski F-Score 6 out of 9 (moderate financial health) .

Value Score

out of 100

Try PRO Free — See Full Breakdown

Key Metrics

P/E Ratio

16.35

P/B Ratio

6.32

EPS

$2.98

Div. Yield

—

PEG Ratio

—

P/S Ratio

—

EV/EBITDA

—

ROE

—

ROA

—

Gross Margin

—

Op. Margin

—

Net Margin

—

Debt/Equity

—

Current Ratio

—

Unlock 19 More Metrics — 7 Days Free

Current vs 5-Year Average

Based on 5 years of SEC filings

Net Margin

—

↑ +2.1pp avg —

Gross Margin

—

↑ +2.1pp avg —

Operating Margin

—

↑ +2.1pp avg —

Return on Equity

—

↑ +2.1pp avg —

Debt / Equity

—

↑ +2.1pp avg —

See How Margins & ROE Have Trended — Try PRO

Revenue & Net Income

Profit Margins

Track Gross, Operating & Net Margins — Try PRO

EPS & Free Cash Flow Per Share

See EPS & Free Cash Flow Trends — Try PRO

Financial Statements

Metric	FY22	FY23	FY24
Revenue	$X.XB	$X.XB	$X.XB
Gross Profit	$X.XB	$X.XB	$X.XB
Operating Income	$X.XB	$X.XB	$X.XB
Net Income	$X.XB	$X.XB	$X.XB
EBITDA	$X.XB	$X.XB	$X.XB
Total Assets	$X.XB	$X.XB	$X.XB
Total Liabilities	$X.XB	$X.XB	$X.XB

Unlock 5 Years of Financials — Start Free Trial

Data sourced from SEC EDGAR and Polygon.io. Methodology. View more Healthcare stocks →

Exelixis, Inc. - Common Stock — Fundamental Analysis Summary

Exelixis, Inc. - Common Stock (EXEL) is currently trading 114% above its Graham Number of $22.72, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries a reasonable trailing P/E ratio of 16.4x.

On financial health, EXEL shows a moderate Piotroski F-Score of 6/9, and strong return on equity of 38.7% (sector average: -20.6%), and manageable leverage with a debt-to-equity ratio of 0.32.

StockPik's composite Value Score for EXEL is 79/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.

EXEL reports a high gross margin of 96.7% (sector average: 40.1%) and a strong operating margin of 38.1%.

EXEL shows revenue growing at 7% year-over-year, with earnings growing at 50%.

Top Value Stocks in Healthcare

Symbol	Name	Price	P/E	Score
EMBC	Embecta Corp. - Common Stock	$3.90	2.1	100
HCM	HUTCHMED (China) Limited - American Depositary Shares	$13.31	5.1	100
GMAB	Genmab A/S - American Depositary Shares	$27.06	1.8	100
CGEN	Compugen Ltd. - Ordinary Shares	$2.71	7.3	100
INVA	Innoviva, Inc. - Common Stock	$22.89	5.8	100

Browse all Healthcare value stocks →

How is the Value Score calculated?

Read our full methodology →

How is the Graham Number calculated?

Benjamin Graham's intrinsic value formula, worked examples, and how to use it →

EXEEZ — EXPAND ENERGY CORPORATION

Expensify, Inc. - Class A Common Stock — EXFY